Clinical trials
SLE (Systemic Lupus) clinical trials
Below are recruiting sle (systemic lupus) clinical trials, each written for real people, not researchers. We’re tracking 215 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07424261Recruiting
Study of anifrolumab for lupus in routine care
This study follows people with lupus who are starting a new medication called anifrolumab (given as a shot under the skin) as part of their regular medical care. It aims to see how well the medicine works in everyday life.
AltenburgAges 18–130 - NCT03138941Recruiting
Checking if a lupus control definition fits Asia-Pacific patients
This study tests whether a specific lupus “low disease activity” target (called LLDAS) works the same way in people across the Asia-Pacific region. It may help doctors use clearer goals to track how well lupus is controlled.
Adelaide, South AustraliaAges 18 years+ - NCT06614270Recruiting
CAR-NK cell therapy for severe autoimmune diseases
This trial tests a new type of immune cell therapy using modified natural killer cells (CAR-NK) that target a protein called CD19 and produce helpful signals (IL-10 and IL-15). It is for people with certain autoimmune diseases that have not improved with standard treatments or have come back after getting better.
Hangzhou, ZhejiangAges 18–65 - NCT05470569Recruiting
Registry study for people with early lupus in Argentina
This is a registry that follows adults with newly diagnosed lupus (within 5 years) to better understand the disease and care needs over time. It may help researchers and doctors learn what to expect early in lupus and improve future treatment planning.
La Plata, Buenos AiresAges 18 years+ - NCT07823478Recruiting
Home urine testing for lupus patients
This study tests whether lupus patients can use a home urine test to monitor their kidney health, which could help catch kidney problems early. It is for patients who have lupus and may have had kidney involvement before, or are at risk of developing it.
New York, New YorkAges 18 years+ - NCT06581562RecruitingPhase 1
Testing rituximab plus AB-101 for autoimmune diseases
This trial tests a new treatment (AB-101) combined with rituximab for people with certain autoimmune diseases like rheumatoid arthritis, pemphigus vulgaris, vasculitis, or lupus. It is for those who have not had success with standard therapies.
Plantation, FloridaAges 18 years+ - NCT06778343Recruiting
Biomarkers study for inflammatory rheumatic diseases
This study is looking for people with ankylosing spondylitis, rheumatoid arthritis, or lupus to help find biomarkers that may make diagnosis easier. If you have one of these conditions and haven't tried biologic therapies, you may be able to join.
LisbonAges 18–65 - NCT07371468RecruitingPhase 1
Study of an experimental drug for lupus, rheumatoid arthritis, and related conditions
This trial tests a new drug called GSK5926371 for people with certain autoimmune diseases that affect the joints, skin, and other tissues. It aims to see if the drug is safe and how well it works.
Buenos AiresAges 18–70 - NCT07352332Recruiting
Immune study of a new treatment for hard-to-treat lupus in children
This study looks at how a treatment called CD3xCD19 BiTE affects the immune system of children with lupus that hasn't gotten better with standard medicines. It uses leftover blood samples to learn more about why some children don't respond to usual treatments.
HangzhouAges 5 years+ - NCT06934447RecruitingPhase 1
CAR-T cell therapy for hard-to-treat lupus in kids
This trial tests a new type of cell therapy, called BCMA/CD70 CAR-T, for children with lupus that hasn't improved with standard treatments. The goal is to see if it can safely reduce disease activity.
Hangzhou, ZhejiangAges 5 years+ - NCT07180537Recruiting
Health course for joint and mood conditions
This study tests an online health course that helps improve diet and self-care to support cell health and wellbeing. It is for people with certain rheumatological conditions like rheumatoid arthritis, lupus, or psoriatic arthritis, who also have mood concerns.
Iowa City, IowaAges 18–100 - NCT07049653Recruiting
Anifrolumab pregnancy safety study
This study looks at pregnancy outcomes in women with lupus (SLE) who were or were not treated with the drug anifrolumab. It helps understand if anifrolumab is safe to use during pregnancy.
Cary, North CarolinaAges 18–130 - NCT07000110Recruiting
Anifrolumab and risk study for lupus patients
This study looks at potential risks of the lupus medication anifrolumab in people with moderate to severe SLE. It focuses on serious infections and malignancies to see how safe the treatment is.
CopenhagenAges 18–130 - NCT06801119RecruitingPhase 1
HN2301 for autoimmune diseases study
This trial tests a new mRNA treatment called HN2301 for people with autoimmune diseases like lupus, scleroderma, or rheumatoid arthritis. It aims to see if the treatment is safe and helps control the disease.
Hefei, AnhuiAges 18–69 - NCT06792799RecruitingEarly Phase 1
CAR-NK cells for B-cell autoimmune diseases
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
Hangzhou, ZhejiangAges 3 years+ - NCT06775912RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
Lianyungang, JiangusAges 18–70 - NCT06659029Recruiting
Study on pregnancy outcomes in lupus patients using anifrolumab
This study tracks the health of pregnant women with moderate to severe lupus who have been treated with anifrolumab, compared to those treated with other lupus medications. It aims to understand how these treatments affect both mother and baby.
Wilmington, North CarolinaAges Any age - NCT06594068RecruitingPhase 4
Anifrolumab in breastfeeding mothers with lupus
This study is looking at how the lupus medicine anifrolumab passes into breast milk and affects mothers and their babies. It is for women who are already taking anifrolumab for lupus and are breastfeeding a baby born at 32 weeks or later.
Las Vegas, NevadaAges 18–130 - NCT06570798RecruitingPhase 2
Testing Two Drugs for Lupus and Rheumatoid Arthritis
This trial tests two study drugs, inebilizumab and blinatumomab, for people with lupus (SLE) or rheumatoid arthritis (RA) that hasn't gotten better with standard treatments. It focuses on those with active disease, especially lupus-related kidney problems.
Scottsdale, ArizonaAges 18–75 - NCT06465147RecruitingPhase 1
Cell therapy for hard-to-treat lupus (REACT-01)
This trial tests a new type of cell therapy (CAR T-cells) to see if it can stop the immune system from attacking the body in severe lupus. It’s for people ages 2–30 whose lupus is not controlled by other treatments and who are willing to be treated at Seattle Children’s Hospital.
Seattle, WashingtonAges 2–30 - NCT04833465Recruiting
Testing a new outcome measure in kids with rheumatology diseases
This study looks at how to measure treatment success in children with juvenile idiopathic arthritis (JIA), lupus (SLE), or fibromyalgia (FM). It may help doctors track symptoms more reliably over time.
Washington D.C., District of ColumbiaAges 5–21 - NCT06316791RecruitingEarly Phase 1
CNCT19 CAR-T therapy for refractory autoimmune diseases
This early-phase study tests a new CAR-T cell therapy (CNCT19) for people with certain autoimmune diseases that have not responded to standard treatments. It targets a protein called CD19 on immune cells to help reset the immune system and reduce disease activity.
Zhengzhou, HenanAges 18–70 - NCT02422875Enrolling by invitation
Study of immune markers in autoimmune disease and lupus
This study looks at blood and immune cell markers (autoantibodies and immune cell “signatures”) to better understand autoimmune conditions, including lupus. It may help researchers identify which markers are linked to disease and how immune cells respond after vaccination.
Atlanta, GeorgiaAges 18 years+
Hear when a new SLE (Systemic Lupus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sle (systemic lupus)?
- Yes. Clin2 currently lists 215 recruiting sle (systemic lupus) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sle (systemic lupus) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sle (systemic lupus) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.